Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company's lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/24/26	$130,000,000	Series A	Forbion Capital Partners Foresite Capital RA Capital	undisclosed